
    
      PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study.
      Patients are randomized to 1 of 2 treatment arms.

      Arm I: Patients receive growth hormone subcutaneously (SC) daily for 2 years. Arm II:
      Patients receive placebo SC daily for 2 years. Quality of life is assessed at the initial
      eligibility screening, then again within 1 month after the initial screening, and then at 1,
      3, and 6 months during study therapy.
    
  